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Cowden syndrome (CS) is a rare dominantly inheritedmultisystemdisorder, characterized by an extraordinarymalignant potential.
In 80% of cases, the human tumor suppressor gene phosphatase and tensin homolog (PTEN) is mutated. We present a case of a
17-year-old boy with genetically confirmed CS and Graves’ disease (GD). At the age of 15, he presented with intention tremor,
palpitations, and marked anxiety. On examination, he had macrocephaly, coarse facies, slight prognathism, facial trichilemmomas,
abdominal keratoses, leg hemangioma, and a diffusely enlarged thyroid gland. He started antithyroid drug (ATD) therapy with
methimazole and, after a 2-year treatment period without achieving a remission status, a total thyroidectomy was performed.
Diagnosis and management of CS should be multidisciplinary. Thyroid disease is frequent, but its management has yet to be fully
defined. The authors present a case report of a pediatric patient with CS and GD and discuss treatment options.
1. Introduction
Cowden syndrome (CS) is a rare dominantly inherited mul-
tisystem complex disorder with high variability and suscep-
tibility, incomplete penetrance, and an identifiable germline
mutation [1–4]. The human tumor suppressor gene, phos-
phatase and tensin homolog (PTEN), ismutated in 80% cases;
mutations in other genes such asKILLIN, SDHB/D, PIK3CA,
and AKT1 are responsible for the rest of the cases [4]. After
gene identification, the incidence of CS was calculated to be 1
in 200,000 [2, 5, 6], which is considered underestimated given
the common manifestations and variable expression of the
syndrome [5].
CS was first described in 1963 by Lloyd and Dennis refer-
ring to their 20-year-old patient who died of breast cancer,
Rachel Cowden, after whom the syndrome was named [2–6].
A slight female predominance appears to be present [2, 7].
It usually occurs in the second or third decade of life and
generally involves the skin, oral mucosa, thyroid, breast,
gastrointestinal tract, genitourinary tract, central nervous
system, and bone, being characterized by an extraordinary
potential for malignant transformation [4–7].
Mucocutaneous manifestations, apparent in 99-100% of
patients, are a pathognomonic feature and usually the first
presenting lesions of the disease. These lesions include
trichilemmomas (hamartomas of the infundibulum of the
hair follicle), facial papules, acral keratoses, oral cavity ver-
rucous or papillomatous papules, benign (e.g., angiomas,
dermal fibromas, lipomas, and neurinomas) and malignant
tumors (e.g.,melanomas, basal cell carcinoma, and squamous
cell carcinomas) [4–7]. Extracutaneous manifestations occur
in about 90% of cases, most often involving the thyroid gland
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(50–70%), with the majority of lesions being adenomatous
goiters or multiple follicular adenomas [4, 5]. Thyroid car-
cinoma has been reported in 3–10%, mostly follicular or
papillary carcinomas, but medullary carcinoma may also
occur, even in children. Other frequent lesions related to CS
are hamartomatous polyps of the digestive tract, fibrocystic
disease of the breast, uterine leiomyoma, and macrocephaly
[5, 8].
Graves’ disease (GD) is an autoimmune disease that
affects the thyroid gland and includes diffuse goiter, hyper-
thyroidism, and ophthalmopathy. Pathophysiology of GD
involves a complex interplay between genetic and envi-
ronmental influences, but the exact mechanisms are not
yet known. GD is a rare condition in childhood, with an
estimated incidence of 0,1–3 per 100,000. Antithyroid drugs
(ATDs) are generally considered the first-line treatment.
Nevertheless, long-term remission rates after 2 or more
years of ATDs have been reported to be low and definitive
treatmentmodalities with radioiodine (RAI) ablation or total
thyroidectomy may be necessary [9].
There are no evidence-based guidelines for management
of these conditions in childhood. Although patients with CS
are known to have a predisposition for thyroid disease, the
exact incidence and pathophysiology are still undefined, as is
the best way to manage those children and adolescents [5].
To the best of our knowledge, reports of pediatric patients
withCS andGDare exceedingly rare in literature.The authors
present a case report of a pediatric patient with CS and GD
and discuss treatment options.
2. Case Description
The patient is a 17-year-old Caucasian boy that presented
with intention tremor, palpitations, and marked anxiety at
age 15. He was medicated with propranolol and hydroxyzine
with partial improvement of symptoms and was referred to a
hospital pediatric appointment.
The adolescent and his father had genetically con-
firmed CS [heterozygous frameshift mutation in exon 5 of
PTEN gene: c.405 406insA (C136Mfs∗44) NM 000314]. The
patient’s father was submitted to a total thyroidectomy for
multinodular goiter at age 23 and died at 60 years old of
brain tumor (anaplastic oligodendroglioma). His paternal
grandfather had thyroid cancer.
Other notable features in our patient’s previous medical
history were macrocephaly, the presence of a hemangioma
in his left lower limb, learning disabilities, and a cognitive
evaluation that concluded that a global delay in cognitive
development with an intelligence quotient (IQ) at the lower
limit of the normal range was present. On physical exam-
ination, he had a coarse facies, slight prognathism, facial
trichilemmomas, abdominal keratoses, and an irregular, elas-
tic, and diffusely enlarged thyroid gland (Figures 1 and 2).
Exophthalmia was not apparent.
Thyroid function tests were consistent with a hyperfunc-
tioning thyroid state: thyrotropin (TSH) < 0,005 IU/mL (nor-
mal range 0,358–3,740 IU/mL), free thyroxine (fT4) 4,97 ng/
dL (normal range 0,76–1,46 ng/dL), free triiodothyronine
Figure 1: Patient photograph showing diffusely enlarged thyroid
gland (frontal view).
Figure 2: Patient photograph showing diffusely enlarged thyroid
gland (left profile).
(fT3) 27,58 pg/mL (normal range 2,18–3,98 pg/mL), with pos-
itive anti-thyroid autoantibodies: thyroid peroxidase anti-
bodies (anti-TPO) > 3340 IU/mL (normal range 0–100 IU/
mL), thyroglobulin antibodies (anti-Tg) > 24400 IU/mL
(normal range 0–344 IU/mL), and thyrotropin receptor anti-
bodies (TRAbs) 14,3 IU/mL (normal range< 1,2 IU/mL).Thy-
roid ultrasonography at diagnosis showed a heterogeneous,
hypoechoic, and high volume goiter (43 × 94 × 38mm left
lobe and 49 × 100 × 44mm right lobe), with no visible
nodules.
He was started on methimazole, maximum dose 20mg/
day, and propranolol treatment, lasting for a 2-year period,
without achieving an euthyroid state.
Thyroid ultrasonography, 2 years after GD diagnosis,
revealed dominant isoechoic solid nodules of 10mm and
12mm in the left and right lobes, respectively. Fine needle
aspiration (FNA) cytology result was benign, consistent with
hyperplastic/adenomatoid nodule (designed according to
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(Figure 3).
A multidisciplinary team, including Pediatric Endocri-
nologist, Adult Endocrinologist, and Pediatric Surgeon, met
in order to discuss the therapeutic options. Attending to the
voluminous goiter and risks inherent to CS, a total thyroidec-
tomy was the definite treatment consensus. That was also
the patient’s choice. Potassium iodide-iodine solution (Lugol)
was used in preoperative preparation and surgery went
uneventful. On gross examination, the surgical specimen
weighed 218 g, with a larger left (95mm) than right lobe
(90mm). The microscopic examination revealed lympho-
cytic thyroiditis (Figures 4–6). Hewas started on replacement
therapywith oral levothyroxine 125 ug/day and he is currently
compensated.
3. Discussion
Early recognition of individuals with CS is essential in order
to start appropriate cancer screening and prevent potential
complications associated with this disorder [1, 4].
Thyroid disease is an important concern among patients
with CS [5]. Clinical guidelines from the National Compre-
hensive Cancer Network (NCCN) recommend that patients
with CS should undergo an annual physical examination
starting at the age of 18 years or 5 years before the youngest age
of diagnosis of a component cancer in the family (whichever
is earlier), with special care to thyroid examination.They also
advocate an annual thyroid ultrasound since the age of 18
years or 5–10 years before the youngest age of diagnosis of a
thyroid cancer in the family (whichever is younger) [10]. On
the other hand, some authors recommend that all patients
with CS should undergo baseline thyroid ultrasound at the
age of diagnosis, with follow-up on a yearly basis, given that
the risk of thyroid cancer begins early in childhood and that
ultrasound is an innocuous screening procedure [3]. Other
studies advocate that thyroid examinations and ultrasound
should be performed from the age of 10 years [6]. Thyroid
surgery, if needed, ought to be a total thyroidectomy, even
if only one side of the thyroid seems to be affected, owing
to the high probability for additional disease and need for
future reoperation [1, 3]. Prophylactic thyroidectomy has
been considered an option for selected patients in whom
lifetime screening may be challenging (e.g., patients with
autism or other developmental disorders) [1, 3]. It may also be
reasonable for CS patients who have nodules and understand
the risks associated with this surgical procedure [1].
For GD, definitive treatment options are RAI or total
thyroidectomy. RAI has been increasingly used in children
except for the very young (less than 5 years of age), although
theoretical concerns of heightened cancer risk still persist.
Surgical treatment is most commonly used in the following
situations: very large goiters (more than 80 g), children
younger than 5 years, planned pregnancy, or patient’s choice
[9]. Currently, the ideal therapeutic approach remains con-
troversial.
Regarding our patient and the available therapeutic
options, RAI could be related to an increased cancer risk,
Figure 3: Fine needle aspiration (FNA) cytology: benign, consistent
with hyperplastic/adenomatoid nodule (H&E, 400x).
Figure 4: Thyroid gland presenting with lymphocytic thyroiditis
and multinodular goiter (H&E, 20x).
Figure 5: Multinodular goiter (H&E, 20x).
Figure 6: Lymphocytic thyroiditis (H&E, 40x).
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which is of special concern in CS; possible surgical com-
plications include anesthetic risk, recurrent laryngeal nerve
injury, hypoparathyroidism, and wound infection [9]. The
experience of treatment centers and specific characteristics of
each patient are definitely decisive factors in the therapeutic
choice.
In the present case, it was decided to perform a total
thyroidectomy given the size of the goiter, increased risk of
malignancy inherent to CS, and patient’s will.
Lugol’s solution was used in the preoperative preparation
to reduce thyroid gland vascularity and potential surgical
blood loss [11].
To the best of our knowledge, reports of pediatric patients
with CS and GD are extremely uncommon. A meta-analysis
from Hall and coworkers reported only 1 case of hyperthy-
roidism among 96 patients with CS and thyroid disease [5].
In conclusion, the diagnosis and the management of CS
should be multidisciplinary. This syndrome has significant
malignant associations, therefore requiring early clinical
suspicion and aggressive screening. Thyroid disease occurs
in about two-thirds of patients, being one of the most
frequent extracutaneous manifestations, thus demanding
special attention and careful monitoring. Despite that, the
management of thyroid disease in CS has yet to be fully
defined. Furthermore, meticulous evaluation of patient’s
family is essential, not only for identification of potential at
risk relatives but also for genetic counseling.
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